PubMed · 15661094
The source did not provide an abstract. Follow the original record for more information.
Explore connections, maps & timelines
Ludwig Kappos. 2005. Interferons in multiple sclerosis.. https://doi.org/10.1016/j.ncl.2004.10.004
Cite the original work for its findings. Save a collection to share your selection of sources.
KEEP EXPLORING
A 6 year old girl presented with flat-topped, skin-colored, partly grouped papules with slightly roughened surface on the left side of the forehead and around the left orbit. In an off-label use imiquimod 5% cream was applied twice a week before bedtime and was rinsed off in the morning. After four weeks of treatment the lesions had vanished completely. We suggest imiquimod 5% cream as a treatment option for juvenile plane warts even in children and in the face.
The present study was undertaken to explore the immunomodulatory activity of ethanolic and water extracts of Capparis zeylanica Linn. (family: Capparidaceae) leaves on neutrophil adhesion test, humoral response to sheep red blood cells, delayed-type hypersensitivity, phagocytic activity and cyclophosphamide-induced myelosuppression. Pre-treatment of water extract (300 mg/kg, oral) of Capparis zeylanica evoked a significant increase in neutrophil adhesion to nylon fibres. The augmentation of humoral immune response to sheep red blood cells by ethanolic and water extracts (150-300 mg/kg) is evidenced by increase in antibody titres in mice. A dose-related increase in both primary and secondary antibody titre was observed. Oral administration of ethanolic and water extracts of Capparis zeylanica leaves, at doses of 150 and 300 mg/kg in mice, dose dependently potentiated the delayed-type hypersensitivity reaction induced by sheep red blood cells. Immunomodulatory activity was also assessed by serological and haematological tests. Capparis zeylanica extracts prevented myelosuppression in mice treated with cyclophosphamide drug. The study comprised the acute toxicity and preliminary phytochemical screening of the ethanol and water extracts.
Cancer testis (CT) antigens are promising candidates for tumor vaccines due to their immunogenicity and tissue-restricted expression. Recently, we identified a novel cancer testis gene, BORIS, whose expression is restricted to male testis after puberty and is strictly absent in non-malignant female tissue. BORIS encodes a DNA-binding protein that shares 11 zing finger (ZF) with transcription factor CTCF and differs at the N- and C-termini. CTCF has been implicated in epigenetic regulation of imprinting, X chromosome inactivation, repression, and activation of cancer testis antigens. BORIS expression has been documented in cancers of diverse histological origin, including, but not limited to breast, prostate, ovary, gastric, liver, endometrial, glia, colon, and esophagus. Interestingly, BORIS induces demethylation and subsequent expression of many cancer-testis genes, including MAGE-A1 and NY-ESO-1, indicating that it is expressed very early in malignancy and might be an attractive candidate for immunotherapy. In this study we tested BORIS as a vaccine in a very aggressive, highly metastatic, and poorly immunogenic murine model of mammary carcinoma. Immunizations with a DNA encoding the mutant form of murine BORIS antigen (pmBORIS lacking DNA-binding function) significantly prolonged survival, and inhibited tumor growth in BALB/c mice inoculated with 4T1 cells. Priming with pmBORIS mixed with molecular adjuvant and boosting with adenoviral vector expressing mBORIS was generally more effective, suggesting that the vaccination protocol could be further optimized. This is the first report demonstrating the feasibility of vaccination with a cancer associated epigenetic regulator for the induction of tumor inhibition.